Patents by Inventor Roy S. Rubinfeld
Roy S. Rubinfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931291Abstract: A first sponge device for use to manipulate and prepare the surface of the epithelium of an eye prior to application of an ophthalmic solution has a handle and a sponge head secured to the handle. The head is made of an absorbent, wicking sponge material and has a non-sharp, tissue preparation surface of predetermined shape for rubbing across the surface of the epithelium layer in order to manipulate the tissue. After the surface is prepared, a second, holding sponge is placed over the eye to act as a reservoir and to hold ophthalmic solution against the eye surface.Type: GrantFiled: January 9, 2020Date of Patent: March 19, 2024Assignee: EPION THERAPEUTICS, INC.Inventors: Roy S. Rubinfeld, Wayne Korteweg
-
Publication number: 20230285451Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: ApplicationFiled: November 14, 2022Publication date: September 14, 2023Inventors: Roy S. RUBINFELD, Raymond A. HARTMAN, Sandy T. FELDMAN
-
Patent number: 11497766Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: GrantFiled: August 3, 2020Date of Patent: November 15, 2022Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
-
Publication number: 20220211542Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: ApplicationFiled: October 1, 2021Publication date: July 7, 2022Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
-
Patent number: 11135090Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: GrantFiled: September 11, 2018Date of Patent: October 5, 2021Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
-
Patent number: 11033429Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: GrantFiled: September 11, 2018Date of Patent: June 15, 2021Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
-
Publication number: 20200360427Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: ApplicationFiled: August 3, 2020Publication date: November 19, 2020Inventors: Roy S. RUBINFELD, Raymond A. HARTMAN, Sandy T. FELDMAN
-
Patent number: 10729716Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: GrantFiled: September 20, 2018Date of Patent: August 4, 2020Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
-
Publication number: 20200146886Abstract: A first sponge device for use to manipulate and prepare the surface of the epithelium of an eye prior to application of an ophthalmic solution has a handle and a sponge head secured to the handle. The head is made of an absorbent, wicking sponge material and has a non-sharp, tissue preparation surface of predetermined shape for rubbing across the surface of the epithelium layer in order to manipulate the tissue. After the surface is prepared, a second, holding sponge is placed over the eye to act as a reservoir and to hold ophthalmic solution against the eye surface.Type: ApplicationFiled: January 9, 2020Publication date: May 14, 2020Inventors: Roy S. RUBINFELD, Wayne KORTEWEG
-
Patent number: 10575986Abstract: A first sponge device for use to manipulate and prepare the surface of the epithelium of an eye prior to application of an ophthalmic solution has a handle and a sponge head secured to the handle. The head is made of an absorbent, wicking sponge material and has a non-sharp, tissue preparation surface of predetermined shape for rubbing across the surface of the epithelium layer in order to manipulate the tissue. After the surface is prepared, a second, holding sponge is placed over the eye to act as a reservoir and to hold ophthalmic solution against the eye surface.Type: GrantFiled: May 12, 2014Date of Patent: March 3, 2020Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Wayne Korteweg
-
Patent number: 10285857Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: GrantFiled: September 21, 2016Date of Patent: May 14, 2019Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
-
Publication number: 20190022134Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: ApplicationFiled: September 20, 2018Publication date: January 24, 2019Inventors: Roy S. Rubinfeld, Raymond A. Hartman (Deceased), Sandy T. Feldman
-
Publication number: 20190008678Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: ApplicationFiled: September 11, 2018Publication date: January 10, 2019Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman (deceased)
-
Publication number: 20190008679Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: ApplicationFiled: September 11, 2018Publication date: January 10, 2019Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman (deceased)
-
Patent number: 10092594Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: GrantFiled: October 26, 2016Date of Patent: October 9, 2018Assignee: CXL Ophthalmics, LLCInventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
-
Patent number: 9622911Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: GrantFiled: March 12, 2014Date of Patent: April 18, 2017Assignee: CXL Ophthalmics, LLCInventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
-
Publication number: 20170071978Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: ApplicationFiled: October 26, 2016Publication date: March 16, 2017Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
-
Publication number: 20170065826Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.Type: ApplicationFiled: September 21, 2016Publication date: March 9, 2017Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
-
Patent number: 9566301Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: GrantFiled: March 28, 2013Date of Patent: February 14, 2017Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
-
Patent number: 9555111Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.Type: GrantFiled: March 27, 2013Date of Patent: January 31, 2017Assignee: CXL Ophthalmics, LLCInventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman